289 related articles for article (PubMed ID: 9043028)
1. Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.
Veldhuis GJ; Willemse PH; Beijnen JH; Boonstra H; Piersma H; van der Graaf WT; de Vries EG
Br J Cancer; 1997; 75(5):703-9. PubMed ID: 9043028
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer.
Papadimitriou CA; Kouroussis C; Moulopoulos LA; Vlahos G; Rodolakis A; Kiamouris C; Diakomanolis E; Gika D; Michalas S; Dimopoulos MA
Cancer; 2001 Oct; 92(7):1856-63. PubMed ID: 11745258
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Herben VM; Panday VR; Richel DJ; Schellens JH; van der Vange N; Rosing H; Beusenberg FD; Hearn S; Doyle E; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Mar; 17(3):747-55. PubMed ID: 10071262
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer.
Fanning J; Hilgers RD
Gynecol Oncol; 1996 Dec; 63(3):323-7. PubMed ID: 8946866
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
[TBL] [Abstract][Full Text] [Related]
7. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
Cairo MS; Shen V; Krailo MD; Bauer M; Miser JS; Sato JK; Blatt J; Blazar BR; Frierdich S; Liu-Mares W; Reaman GH
J Pediatr Hematol Oncol; 2001 Jan; 23(1):30-8. PubMed ID: 11196267
[TBL] [Abstract][Full Text] [Related]
8. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin.
Brugger W; Frisch J; Schulz G; Pressler K; Mertelsmann R; Kanz L
J Clin Oncol; 1992 Sep; 10(9):1452-9. PubMed ID: 1517788
[TBL] [Abstract][Full Text] [Related]
9. The limits of chemotherapy dose intensification using granulocyte colony stimulating factor alone in extensive small cell lung cancer.
Trillet-Lenoir V; Soler P; Arpin D; Bohas C; Riou R; Court-Fortune I; Ecochard D; Perol M; Cordier JF
Lung Cancer; 1996 Jun; 14(2-3):331-41. PubMed ID: 8794414
[TBL] [Abstract][Full Text] [Related]
10. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
Nagao S; Nishikawa T; Hanaoka T; Kurosaki A; Iwasa N; Hasegawa K; Fujiwara K
Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
Graziano SL; Valone FH; Herndon JE; Crawford J; Richards F; Rege VB; Clamon G; Green MR
Lung Cancer; 1996 Jun; 14(2-3):315-29. PubMed ID: 8794413
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-Ifosfamide-gemcitabine as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and Paclitaxel.
Polyzos A; Tsavaris N; Gogas H; Lagadas A; Polyzos K; Giannakopoulos K; Felekouras E; Tsigris C; Karatzas T; Papadopoulos O; Giannopoulos A
Anticancer Res; 2009 Jul; 29(7):2681-6. PubMed ID: 19596946
[TBL] [Abstract][Full Text] [Related]
13. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Iaffaioli RV; Tortoriello A; Santangelo M; Turitto G; Libutti M; Benassai G; Frattolillo A; Ciccarelli PD; De Rosa P; Crovella F; Carbone I; Barbarisi A
Clin Oncol (R Coll Radiol); 2000; 12(4):251-5. PubMed ID: 11005695
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours.
Kosmas C; Tsavaris NB; Polyzos A; Malamos NA; Katsikas M; Antonopoulos MJ
Br J Cancer; 2000 Jan; 82(2):300-7. PubMed ID: 10646881
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma.
Kosmas C; Tsavaris NB; Polyzos A; Kalofonos HP; Sepsas E; Malamos NA; Vadiaka M; Dosios T; Antonopoulos MJ
Cancer; 2000 Aug; 89(4):774-82. PubMed ID: 10951340
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Palackdharry CS
Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
[TBL] [Abstract][Full Text] [Related]
18. A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.
Bunnell CA; Thompson L; Buswell L; Berkowitz R; Muto M; Sheets E; Shulman LN
Cancer; 1998 Feb; 82(3):561-6. PubMed ID: 9452275
[TBL] [Abstract][Full Text] [Related]
19. A phase II double-blind randomized study of the simultaneous administration of recombinant human interleukin-6 and recombinant human granulocyte colony-stimulating factor following paclitaxel and carboplatin chemotherapy in patients with advanced epithelial ovarian cancer.
Hochster H; Speyer JL; Mandeli JP; Runowicz C; Wadler S; Berk G; Wallach R; Holland JF
Gynecol Oncol; 1999 Mar; 72(3):292-7. PubMed ID: 10053098
[TBL] [Abstract][Full Text] [Related]
20. The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study.
Di Leo A; Bajetta E; Nolè F; Biganzoli L; Ferrari L; Oriana S; Riboldi G; Bohm S; Spatti G; Raspagliesi F
Br J Cancer; 1994 May; 69(5):961-6. PubMed ID: 7514030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
